Peking University China-Japan Friendship School of Clinical Medicine, Beijing, China; China-Japan Friendship Hospital, Yinghuadong Road, Beijing 100029, Chaoyang District, China.
Graduate School of Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China; Department of Colorectal Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Transpl Immunol. 2022 Aug;73:101605. doi: 10.1016/j.trim.2022.101605. Epub 2022 Apr 27.
Passenger lymphocyte syndrome (PLS) is an immune-mediated hemolysis that occurs after ABO-mismatched kidney transplantation. PLS is caused by donor lymphocytes producing antibodies to recipient red blood cells, resulting in hemolysis. The incidence of PLS has been reported to be approximately 20% in patients with ABO-mismatched groups. Nevertheless, there is no comprehensive review of PLS following renal transplantation. In this review, we systematically summarized the data of patients with PLS after renal transplantation to help clinicians diagnose and treat more effectively.
A systematic review was conducted using PubMed, Embase, and Web of Science. All relevant data were collected, including age, sex, and clinical and immune parameters.
A total of 91 published cases were identified. The age ranged from 9 to 70 years old and 58.2% were male. Eighty-six cases were only kidney transplantations, one was liver-kidney transplantation, three were pancreas-kidney transplantations, and one was intestinal-kidney transplantation. Of these cases, 27 received kidneys from deceased donors, whereas 40 received kidneys from living donors. Most patients showed immune hemolysis dominated by anaemia, which was significantly improved after symptomatic support treatment, such as blood transfusion and erythropoietin injection.
PLS is an immune-mediated disease that can occur in patients with ABO-mismatched renal transplantation, which commonly causes hemolysis, although death or deformities of the graft can also occur in patients with the disorder. Symptomatic supportive treatment is an effective treatment scheme at present, but more effective treatment and prevention schemes still need to be explored.
乘客淋巴细胞综合征(PLS)是一种 ABO 血型不合肾移植后发生的免疫介导性溶血。PLS 是由供者淋巴细胞产生针对受者红细胞的抗体引起的溶血。据报道,ABO 血型不合组患者的 PLS 发生率约为 20%。然而,目前尚无关于肾移植后 PLS 的全面综述。在本综述中,我们系统地总结了肾移植后 PLS 患者的数据,以帮助临床医生更有效地诊断和治疗。
通过 PubMed、Embase 和 Web of Science 进行系统综述。收集所有相关数据,包括年龄、性别和临床及免疫参数。
共确定了 91 例已发表的病例。年龄从 9 岁到 70 岁不等,其中 58.2%为男性。86 例仅为肾移植,1 例为肝肾联合移植,3 例为胰肾联合移植,1 例为肠肾联合移植。这些病例中,27 例接受了已故供者的肾脏,40 例接受了活体供者的肾脏。大多数患者表现为以贫血为主的免疫性溶血,经输血和注射促红细胞生成素等对症支持治疗后明显改善。
PLS 是一种 ABO 血型不合肾移植后可发生的免疫介导性疾病,常导致溶血,但该疾病患者也可出现移植物死亡或畸形。目前对症支持治疗是一种有效的治疗方案,但仍需要探索更有效的治疗和预防方案。